Kurs & Likviditet
Kalender
2024-11-12 | Kvartalsrapport 2024-Q3 |
2024-07-25 | Kvartalsrapport 2024-Q2 |
2024-04-25 | Kvartalsrapport 2024-Q1 |
2024-04-11 | Årsstämma 2024 |
2024-02-22 | Halvårsutdelning AZN 20.65 |
2024-02-08 | Bokslutskommuniké 2023 |
2023-11-09 | Kvartalsrapport 2023-Q3 |
2023-08-10 | Halvårsutdelning AZN 9.64 |
2023-07-28 | Kvartalsrapport 2023-Q2 |
2023-04-27 | Årsstämma 2023 |
2023-04-27 | Kvartalsrapport 2023-Q1 |
2023-02-23 | Halvårsutdelning AZN 20.69 |
2023-02-09 | Bokslutskommuniké 2022 |
2022-11-10 | Kvartalsrapport 2022-Q3 |
2022-08-11 | Halvårsutdelning AZN 9.49 |
2022-07-29 | Kvartalsrapport 2022-Q2 |
2022-04-29 | Kvartalsrapport 2022-Q1 |
2022-04-29 | Årsstämma 2022 |
2022-02-24 | Halvårsutdelning AZN 18 |
2022-02-10 | Bokslutskommuniké 2021 |
2021-11-12 | Kvartalsrapport 2021-Q3 |
2021-08-12 | Halvårsutdelning AZN 7.72 |
2021-07-29 | Kvartalsrapport 2021-Q2 |
2021-05-11 | Årsstämma 2021 |
2021-04-30 | Kvartalsrapport 2021-Q1 |
2021-02-25 | Halvårsutdelning AZN 15.76 |
2021-02-11 | Bokslutskommuniké 2020 |
2020-11-05 | Kvartalsrapport 2020-Q3 |
2020-08-13 | Halvårsutdelning AZN 7.87 |
2020-07-30 | Kvartalsrapport 2020-Q2 |
2020-04-29 | Årsstämma 2020 |
2020-04-29 | Kvartalsrapport 2020-Q1 |
2020-02-27 | Halvårsutdelning AZN 18.32 |
2020-02-14 | Bokslutskommuniké 2019 |
2019-10-24 | Kvartalsrapport 2019-Q3 |
2019-08-08 | Halvårsutdelning AZN 8.49 |
2019-07-25 | Kvartalsrapport 2019-Q2 |
2019-04-26 | Kvartalsrapport 2019-Q1 |
2019-04-26 | Årsstämma 2019 |
2019-02-28 | Halvårsutdelning AZN 17.46 |
2019-02-14 | Bokslutskommuniké 2018 |
2018-11-08 | Kvartalsrapport 2018-Q3 |
2018-08-09 | Halvårsutdelning AZN 7.92 |
2018-07-26 | Kvartalsrapport 2018-Q2 |
2018-05-18 | Kvartalsrapport 2018-Q1 |
2018-05-18 | Årsstämma 2018 |
2018-02-15 | Halvårsutdelning AZN 14.97 |
2018-02-02 | Bokslutskommuniké 2017 |
2017-11-09 | Kvartalsrapport 2017-Q3 |
2017-08-10 | Halvårsutdelning AZN 7.4 |
2017-07-27 | Kvartalsrapport 2017-Q2 |
2017-04-27 | Årsstämma 2017 |
2017-04-27 | Kvartalsrapport 2017-Q1 |
2017-02-16 | Halvårsutdelning AZN 16.57 |
2017-02-02 | Bokslutskommuniké 2016 |
2016-11-10 | Kvartalsrapport 2016-Q3 |
2016-08-11 | Halvårsutdelning AZN 7.81 |
2016-07-28 | Kvartalsrapport 2016-Q2 |
2016-04-29 | Kvartalsrapport 2016-Q1 |
2016-04-29 | Årsstämma 2016 |
2016-02-18 | Halvårsutdelning AZN 16.26 |
2016-02-04 | Bokslutskommuniké 2015 |
2015-11-05 | Kvartalsrapport 2015-Q3 |
2015-08-13 | Halvårsutdelning AZN 7.71 |
2015-07-30 | Kvartalsrapport 2015-Q2 |
2015-04-24 | Kvartalsrapport 2015-Q1 |
2015-04-24 | Årsstämma 2015 |
2015-02-19 | Halvårsutdelning AZN 15.62 |
2015-02-05 | Bokslutskommuniké 2014 |
2014-11-06 | Kvartalsrapport 2014-Q3 |
2014-08-13 | Halvårsutdelning AZN 6.2 |
2014-07-31 | Kvartalsrapport 2014-Q2 |
2014-04-24 | Kvartalsrapport 2014-Q1 |
2014-04-24 | Årsstämma 2014 |
2014-02-19 | Halvårsutdelning AZN 12.41 |
2014-02-06 | Bokslutskommuniké 2013 |
2013-10-31 | Kvartalsrapport 2013-Q3 |
2013-08-14 | Halvårsutdelning AZN 5.92 |
2013-08-01 | Kvartalsrapport 2013-Q2 |
2013-08-01 | Analytiker möte 2013 |
2013-04-25 | Kvartalsrapport 2013-Q1 |
2013-04-25 | Årsstämma 2013 |
2013-02-13 | Halvårsutdelning AZN 12.08 |
2013-01-31 | Bokslutskommuniké 2012 |
2012-10-25 | Kvartalsrapport 2012-Q3 |
2012-10-25 | Analytiker möte 2012 |
2012-08-08 | Halvårsutdelning AZN 6.26 |
2012-07-26 | Kvartalsrapport 2012-Q2 |
2012-04-26 | Kvartalsrapport 2012-Q1 |
2012-04-26 | Årsstämma 2012 |
2012-02-15 | Halvårsutdelning AZN 13.21 |
2012-02-02 | Bokslutskommuniké 2011 |
2011-10-27 | Kvartalsrapport 2011-Q3 |
2011-08-03 | Halvårsutdelning AZN 5.33 |
2011-07-28 | Kvartalsrapport 2011-Q2 |
2011-04-28 | Årsstämma 2011 |
2011-04-28 | Kvartalsrapport 2011-Q1 |
2011-02-02 | Halvårsutdelning AZN 11.99 |
2011-01-27 | Bokslutskommuniké 2010 |
2010-10-28 | Kvartalsrapport 2010-Q3 |
2010-08-04 | Halvårsutdelning AZN 5.12 |
2010-07-29 | Kvartalsrapport 2010-Q2 |
2010-04-29 | Kvartalsrapport 2010-Q1 |
2010-02-03 | Halvårsutdelning AZN 12.43 |
2010-01-28 | Bokslutskommuniké 2009 |
2009-10-29 | Kvartalsrapport 2009-Q3 |
2009-08-05 | Halvårsutdelning AZN 4.41 |
2009-07-30 | Kvartalsrapport 2009-Q2 |
2009-04-30 | Kvartalsrapport 2009-Q1 |
2009-04-30 | Årsstämma 1 |
2009-02-04 | Halvårsutdelning AZN 12.02 |
2008-08-06 | Halvårsutdelning AZN 3.34 |
2008-02-06 | Halvårsutdelning AZN 8.61 |
2007-08-08 | Halvårsutdelning AZN 3.49 |
2007-02-07 | Halvårsutdelning AZN 8.6 |
2006-08-09 | Halvårsutdelning AZN 3.6 |
2006-02-08 | Halvårsutdelning AZN 7.02 |
2005-08-10 | Halvårsutdelning AZN 2.99 |
2005-02-09 | Halvårsutdelning AZN 4.497 |
2004-08-11 | Halvårsutdelning AZN 2.2 |
2004-02-18 | Halvårsutdelning AZN 3.91 |
2003-08-20 | Halvårsutdelning AZN 2.07 |
2003-02-19 | Halvårsutdelning AZN 3.99 |
2002-08-21 | Halvårsutdelning AZN 2.21 |
2002-02-20 | Halvårsutdelning AZN 5.01 |
2001-08-22 | Halvårsutdelning AZN 2.44 |
2001-02-21 | Halvårsutdelning AZN 4.49 |
2000-09-04 | Halvårsutdelning AZN 2.1 |
2000-03-08 | Halvårsutdelning AZN 4.01 |
1999-09-06 | Halvårsutdelning AZN 1.89 |
1999-04-01 | Split AZN 1:0.5045 |
1997-05-26 | Split AZN 1:2 |
1993-06-14 | Split AZN 1:5 |
1987-06-04 | Split AZN 1:2 |
Beskrivning
Land | Storbritannien |
---|---|
Lista | Large Cap Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
AstraZeneca today issued the following statement from Pascal Soriot, Chief Executive Officer.
"We are deeply saddened by the news that José Baselga, Executive Vice President Oncology R&D, and member of our Senior Executive Team, has passed away.
An outstanding scientific leader, José leaves a lasting legacy in the scientific community and here at AstraZeneca. He set our Oncology R&D function on a remarkable trajectory, and his visionary leadership, deep scientific expertise and strategic insight have delivered so many achievements that we can all be proud of and that will benefit patients' lives in the years to come.
José championed our transformative collaborations with Daiichi-Sankyo in relation to the clinical development of Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan, two medicines which have demonstrated great potential to benefit cancer patients. He led a team to accelerate other exciting new science in antibody-drug conjugates, cell therapy, epigenetics, as well as new cancer treatments. He also championed the use of real-world evidence and digital tools to transform the way we design and implement clinical trials.
José built a world-class Oncology R&D team who will miss him dearly, just as all his colleagues will throughout our entire Company.
José was more than a colleague to me. He was a friend, and someone I immensely respected and cherished. I will enormously miss having him alongside me, and I will continue to be inspired by his work and vision.
My heart goes out to his wife Silvia and his four children."
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).
Contacts
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).
Christina Malmberg HägerstrandPresschef AstraZeneca AB och Norden Baltikum+ 46 8 552 53 106